SHL – UBS rates the stock as Downgrade to Sell from Neutral

By Broker News | More Articles by Broker News

The FY11 headline net profit was in-line, but the broker notes that on a trading basis, the company booked a "strong" result when compared to global peers.

However, some undisclosed purchases and higher debt margins have seen the company’s interest costs rise some 30%. That, and a slightly higher tax rate were certainly not expected, notes the broker.

The broker notes the higher interest will take a bite from earnings, as will weaker market. Thus, the price target is cut to $10.60 (from $12.00), seeing the recommendation dropped to Sell from Neutral.
Sector: Health Care Equipment & Services.

Target price is $10.60.Current Price is $11.29. Difference: ($0.69) – (brackets indicate current price is over target). If SHL meets the UBS target it will return approximately -7% (excluding dividends, fees and charges – negative figures indicate an expected loss).

Broker News

About Broker News

FNArena's Australian Broker Call, is your daily news report on the latest recommendation, valuation, forecast and opinions recently published by Stockbrokers.

View more articles by Broker News →